Header Logo

Connection

GEORGE R BLUMENSCHEIN to Biomarkers, Tumor

Back to Details
This is a "connection" page, showing publications GEORGE R BLUMENSCHEIN has written about Biomarkers, Tumor.
GEORGE R BLUMENSCHEIN
Connection Strength
0.680
Biomarkers, Tumor
  1. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)?. Ann Oncol. 2015 May; 26(5):894-901.
    View in: PubMed
    Score: 0.128
  2. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75.
    View in: PubMed
    Score: 0.117
  3. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev. 2013 Jun; 39(4):313-20.
    View in: PubMed
    Score: 0.110
  4. Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. Cancer Biomark. 2011-2012; 10(6):287-98.
    View in: PubMed
    Score: 0.096
  5. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61.
    View in: PubMed
    Score: 0.028
  6. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42.
    View in: PubMed
    Score: 0.028
  7. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52.
    View in: PubMed
    Score: 0.027
  8. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer. 2013 Jan 01; 119(1):7-15.
    View in: PubMed
    Score: 0.027
  9. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
    View in: PubMed
    Score: 0.026
  10. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53.
    View in: PubMed
    Score: 0.025
  11. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol. 2007 Nov; 31(11):1645-52.
    View in: PubMed
    Score: 0.019
  12. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.012
  13. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 06; 14(6):1021-1031.
    View in: PubMed
    Score: 0.011
  14. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. Oncologist. 2014 Oct; 19(10):1040-1.
    View in: PubMed
    Score: 0.008
  15. Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer. 2013 Oct; 13(5):378-84.
    View in: PubMed
    Score: 0.007
  16. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013 Jan; 24(1):220-5.
    View in: PubMed
    Score: 0.007
  17. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012 Apr 15; 18(8):2269-77.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.